Priavoid GmbH

12 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Apr 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 1, 2027
The maintenance fee for Cyclic, Amyloid Beta-Binding Peptides and the Use Thereof. (US 10,428,127) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,464,118	Polymers containing multivalent amyloid-beta-binding D-peptides and their use In force Ends no later than Apr 5, 2033 · From the USPTO record	In force	Ends no later than Apr 5, 2033	From the USPTO record
US 9,591,845	Method for Treating Blood, Blood Products and Organs In force Term ends Apr 5, 2033 · High confidence	In force	Term ends Apr 5, 2033	High confidence
US 10,030,056	Agents for Preventing and Treating HIV and Other Viral Infections In force Term ends Apr 5, 2033 · High confidence	In force	Term ends Apr 5, 2033	High confidence
US 10,123,530	Method for Treating Blood, Blood Products and Organs In force Term ends Apr 5, 2033 · Low confidence	In force	Term ends Apr 5, 2033	Low confidence
US 10,167,318	D-Enantiomeric Peptides Derived from D3 and Use Thereof In force (reinstated) Term ends Apr 5, 2033 · Low confidence	In force (reinstated)	Term ends Apr 5, 2033	Low confidence
US 10,772,321	Method for Treating Blood, Blood Products and Organs In force Term ends Apr 5, 2033 · Medium confidence	In force	Term ends Apr 5, 2033	Medium confidence
US 10,889,618	Novel D-Enantiomeric Peptides Derived from D3 and Use Thereof In force Term ends Apr 5, 2033 · Low confidence	In force	Term ends Apr 5, 2033	Low confidence
US 10,995,118	Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease In force Ends no later than Apr 5, 2033 · From the USPTO record	In force	Ends no later than Apr 5, 2033	From the USPTO record
US 11,274,125	Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of Alzheimer's disease In force Term ends Apr 29, 2033 · From the USPTO record	In force	Term ends Apr 29, 2033	From the USPTO record
US 10,428,127	Cyclic, Amyloid Beta-Binding Peptides and the Use Thereof. In force Term ends Dec 28, 2034 · High confidence	In force	Term ends Dec 28, 2034	High confidence

10 of 12 patents shown.

Pro members see all 12.

Pro members: see all 12 patents

Also on record, not counted in the 12: 4 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending

List them